Summary of KEYNOTE-A18 by Sergio Cifuentes Canaval

Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, shared on X/Twitter:

“KEYNOTE-A18:

• Pembrolizumab and chemoradiotherapy (CRT) in locally advanced cervical cancer (LACC)
• mPFS NR in pembrolizumab group
• 24m PFS: 68% vs 57%
• Pembrolizumab and CRT led to a 30% reduction in DR
• OS at 24 months: 87% vs 81%
• Grade 3 or higher adverse effects: 75% vs 69%”

Read further.
Source: Sergio Cifuentes Canaval/X

About OncoDaily

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.